Literature DB >> 29765948

Congenital Orbital Rhabdomyosarcoma.

Masoomeh Eghtedari1, Amir Reza Farsiani1, Mohammad Reza Bordbar2.   

Abstract

Rhabdomyosarcoma (RMS) is the most common malignant tumor of the orbit in children, but it is rarely present at birth. We report a large congenital orbital RMS with intracranial extension in a newborn baby. A newborn baby girl was referred to our hospital due to severe right-eye exophthalmia. Imaging studies showed an orbital mass with intracranial extension. Treatment was started with a course of neoadjuvant chemotherapy followed by right orbital exenteration and intracranial resection of the tumor. Histologic examination of the mass showed undifferentiated malignant small-cell tumor. Immunohistochemical study proved it to be RMS. The patient was categorized as intermediate-risk RMS and chemotherapy was continued accordingly with VAC regimen. In spite of treatment, the infant developed intracranial recurrence at the age of 6 months and died 1 month later. Congenital orbital RMS has a poor prognosis. Reconstruction surgery should be deferred due to high rate of recurrence and low chance of survival. A multidisciplinary approach might increase the survival of these patients.

Entities:  

Keywords:  Congenital tumor; Exenteration; Orbit; Rhabdomyosarcoma

Year:  2017        PMID: 29765948      PMCID: PMC5939714          DOI: 10.1159/000481533

Source DB:  PubMed          Journal:  Ocul Oncol Pathol        ISSN: 2296-4657


  6 in total

1.  Orbital cyst: prenatal diagnosis.

Authors:  Arun D Singh; Elias I Traboulsi; Janet Reid; Donna Patno; Jeffrey Chapa; Ricardo Rodriguez; Sabine Iben; Lynn Schoenfield
Journal:  Ophthalmology       Date:  2009-10       Impact factor: 12.079

Review 2.  Developmental origins of fusion-negative rhabdomyosarcomas.

Authors:  Ken Kikuchi; Brian P Rubin; Charles Keller
Journal:  Curr Top Dev Biol       Date:  2011       Impact factor: 4.897

3.  Treatment of orbital rhabdomyosarcoma: survival and late effects of treatment--results of an international workshop.

Authors:  O Oberlin; A Rey; J Anderson; M Carli; R B Raney; J Treuner; M C Stevens
Journal:  J Clin Oncol       Date:  2001-01-01       Impact factor: 44.544

4.  Prognostic factors in 951 nonmetastatic rhabdomyosarcoma in children: a report from the International Rhabdomyosarcoma Workshop.

Authors:  C Rodary; E A Gehan; F Flamant; J Treuner; M Carli; A Auquier; H Maurer
Journal:  Med Pediatr Oncol       Date:  1991

5.  Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.

Authors:  Carola A S Arndt; Julie A Stoner; Douglas S Hawkins; David A Rodeberg; Andrea A Hayes-Jordan; Charles N Paidas; David M Parham; Lisa A Teot; Moody D Wharam; John C Breneman; Sarah S Donaldson; James R Anderson; William H Meyer
Journal:  J Clin Oncol       Date:  2009-09-21       Impact factor: 44.544

6.  A clinical update and radiologic review of pediatric orbital and ocular tumors.

Authors:  Ajay A Rao; John H Naheedy; James Y-Y Chen; Shira L Robbins; Hema L Ramkumar
Journal:  J Oncol       Date:  2013-03-12       Impact factor: 4.375

  6 in total
  1 in total

1.  Rhabdomyosarcoma masquerading as orbital cellulitis.

Authors:  Rajesh Subhash Joshi; Tanmay Surwade; Aswini Rasal
Journal:  Indian J Ophthalmol       Date:  2022-07       Impact factor: 2.969

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.